[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371085-105":59,"doc-detail-371085-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","acute-dyspnoea-in-cancer-patients-prevalence-of-acute-heart-failure-resource-use-and-diagnostic-accuracy-of-natriuretic-peptides","Acute dyspnoea in cancer patients - Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides","","Aims Among patients with acute dyspnoea, the prevalence of acute heart failure (AHF), associated resource use, and diagnostic accuracy of natriuretic peptides were previously unclear. Methods Patients presenting to emergency departments were prospectively enrolled in a multicentre diagnostic study with central AHF adjudication by independent cardiologists. BNP and NT-proBNP were measured at presentation, while cancer status, resource use, and long-term outcomes were assessed. Results Among 2153 patients, 22.0% had active or past cancer; AHF was common in both groups but diagnostic performance of rales, pleural effusion, and NT-proBNP was lower in cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/acute-dyspnoea-in-cancer-patients-prevalence-of-acute-heart-failure-resource-use-and-diagnostic-accuracy-of-natriuretic-peptides/371085/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/acute-dyspnoea-in-cancer-patients-prevalence-of-acute-heart-failure-resource-use-and-diagnostic-accuracy-of-natriuretic-peptides/371085.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim regarding natriuretic peptides in cancer patients with acute dyspnoea?","Question",{"text":112,"@type":113},"To determine the prevalence of acute heart failure, resource use, and the diagnostic accuracy of natriuretic peptides in patients presenting with acute dyspnoea.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was acute heart failure diagnosed in the study?",{"text":117,"@type":113},"AHF was centrally adjudicated by two independent cardiologists based on current guidelines, using BNP and NT-proBNP measurements taken at emergency presentation.",{"name":119,"@type":110,"acceptedAnswer":120},"Did natriuretic peptide performance differ between cancer and non-cancer patients?",{"text":121,"@type":113},"Yes. The AUC of NT-proBNP was lower in cancer than in non-cancer patients, while BNP performance was similar.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371085,1790239898,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","European Journal of Heart Failure (2025) 27, 2100–2111 RESEARCH ARTICLE  \n doi:10.1002/ejhf.3752  \nAcute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides  \nPaolo Bima 1,2 *†, Desirée Wussler 1,3†, Pedro Lopez-Ayala 1†, Maria Belkin 1,4, Albina Nowak5,6, Xueting Lin 1, Ivo Strebel 1, Fabiana Sgueglia 1, Eleni Michou 1, Androniki Papachristou 1,7, Laureve Chollet 1,7, Codruta Popescu 1,7,  \nNikola Kozhuharov 1,8, Samyut Shrestha 1, Gabriela Kuster 1, Katharina Rentsch9, Arnold Von Eckardstein 10, Mascha Binder 11, Felix Mahfoud 1, Tobias Breidthardt 1,7, and Christian Mueller 1*  \n1 Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland; 2 Department of Medical Sciences, University of Torino, Turin, Italy; 3 Department of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada; 4 Department of Hematology, University Hospital Basel, Basel, Switzerland; 5 Department of Endocrinology and Clinical Nutrition, University Hospital Zürich, Zürich, Switzerland; 6 Division of Internal Medicine, University Psychiatry Clinic Zurich, Zurich, Switzerland; 7 Department of Internal Medicine, University Hospital Basel, Basel, Switzerland; 8 Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland; 9 Laboratory Medicine, University Hospital Basel, University of Basel, Basel, Switzerland; 10Laboratory Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland; and 11 Department of Oncology, University Hospital Basel, University of Basel, Basel, Switzerland  \nReceived 2 1 January 2025; revised 19 May 2025; accepted 10 June 2025 ; online publish-ahead-of-print 30 June 2025  \nAims Among cancer patients presenting with acute dyspnoea, the prevalence of acute heart failure (AHF), resource use  \nand diagnostic accuracy of natriuretic peptides remain unknown. This study aimed to address these knowledge gaps.  \n............................................................... ................................................................ ......................................  \nMethods Patients presenting with acute dyspnoea to the emergency department (ED) were prospectively enrolled in a  \nand results multicentre diagnostic study. AHF was centrally adjudicated by two independent cardiologists based on current  \nguidelines. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) concentrations were measured at ED presentation. Cancer status, resource use, and long-term outcomes were prospectively assessed. Among 2153 patients, 473 (22.0%) had an active or past cancer. AHF was the most common final diagnosis in both cancer and non-cancer patients (44.4% vs. 51.0%, p = 0.01). Among the alternative diagnoses, pneumonia and cancer-related dyspnoea were more frequent in patients with cancer, while anxiety disorder/hyperventilation was frequent in patients without cancer. Hospitalization rate and length of hospital stay were both higher in cancer patients (p \u003C 0.01). Among AHF-related signs, rales and pleural effusion showed a significant interaction with cancer status and had lower diagnostic accuracy in cancer patients. The area under the curve (AUC) of NT-proBNP was lower in cancer than in non-cancer patients (0.89 vs. 0.93, p = 0.01), while that of BNP was similar (0.93 vs. 0.95, p = ns). This difference was mainly due to active cancers.  \n............................................................... ................................................................ ......................................  \nConclusions Acute heart failure was the most common diagnosis in cancer patients presenting with acute dyspnoea. Rales, pleural  \neffusion, and NT-proBNP had lower diagnostic accuracy versus patients without cancer, while that of BNP remained robust.  \n..................................................","cbCainfWLifFSwF7","https://ap.wps.com/l/cbCainfWLifFSwF7","pdf",1519107,12,"English","# Aims\n# Methods and results\n## Prevalence and diagnostic performance\n## Resource use and outcomes\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What was the study aim regarding natriuretic peptides in cancer patients with acute dyspnoea?\",\"answer\":\"To determine the prevalence of acute heart failure, resource use, and the diagnostic accuracy of natriuretic peptides in patients presenting with acute dyspnoea.\"},{\"question\":\"How was acute heart failure diagnosed in the study?\",\"answer\":\"AHF was centrally adjudicated by two independent cardiologists based on current guidelines, using BNP and NT-proBNP measurements taken at emergency presentation.\"},{\"question\":\"Did natriuretic peptide performance differ between cancer and non-cancer patients?\",\"answer\":\"Yes. The AUC of NT-proBNP was lower in cancer than in non-cancer patients, while BNP performance was similar.\"}]","Acute dyspnoea in cancer patients - Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides | PDF",1790191211,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18fc4633377b66509c416dbc048bace8.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7811c62232065994056e1ddf6ff38f6.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81a9d6aaf32032ce8f0d31c70302edbe.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42ef479653a4e8d6476220a3876ce555.webp",980,1287]